EXOZ - Bathi resik saben saham (EPS TTM) Invizyne Technologies

The early stage of commercialization is forcing eXoZymes Inc (EXOZ) to offer flexible pricing to partners. This is confirmed by the rolling net income per share on the GURU.Markets chart, where the value remains at -1.20. Growth is driven by cell-free chemical synthesis methods, while a lean headcount is maintained through an R&D model and cloud-based training of AI algorithms.

This indicator measures the fundamental equity return of the business by calculating net earnings per share over a rolling annual period to identify trend inflection points. By analyzing the trailing 12-month earnings per share, investors assess the resilience of eXoZymes Inc. (EXOZ), whose financial stability currently depends critically on the transition of cell-free synthesis to industrial scaling and external financing.